Conference Correspondent

CHICAGO—Results from an important phase 3 trial presented at the plenary session could lead to prolonged treatment with adjuvant imatinib for gastrointestinal stromal tumors (GIST).
CHICAGO—The phase 3 ACT-1 trial suggests that amrubicin may have some advantages over topotecan as secondline treatment for small-cell lung cancer (SCLC).
CHICAGO—Several studies addressed key questions in the treatment of non-Hodgkin lymphoma (NHL). One evaluated a shorter, more intense rituximab- based regimen, and another evaluated the benefit of autologous stem-cell transplantation (ASCT) in high-risk patients.

CHICAGO—Flaxseed failed to have a significant effect on reducing hot flashes in women compared with placebo, according to results of a randomized, placebo-controlled trial supported by the North Central Cancer Treatment Group. The study included breast cancer survivors as well as women who had never had breast cancer who experienced frequent hot flashes throughout the day and night.

CHICAGO—Both patients and practitioners realize the importance of psychosocial issues, but today’s cancer care often fails to address them. Steps to resolve this problem are under way, according to experts at an education session.

CHICAGO—Decitabine extends overall survival and improves response rates compared with standard therapies in the treatment of older patients with newly diagnosed acute myelogenous leukemia (AML), said Xavier G. Thomas, MD, PhD.

The treatment options for older patients with AML are limited. Intensive chemotherapy is generally poorly tolerated in this group, the initial mortality rate is high (exceeding 30% at 8 weeks), the response rate to chemotherapy is poor, and relapse rates are high.

CHICAGO—Exemestane appears to be a good alternative to tamoxifen for prevention of breast cancer in postmenopausal women, according to results of the randomized, placebo-controlled MAP.3 trial.

CHICAGO—Oncology nurses know that nutrition interventions can help their patients, both during and after active treatment. But the evidence is scant, and personalizing it for each patient can be a challenge. To help, nutrition experts provided useful tips for nurses, along with a discussion of the evidence.

BOSTON—Treating patients with cancer who are morbidly obese presents unexpected challenges according to Vita Norton, RN, BSN, OCN, and Michelle Howard, RN, BSN, of Mass - achusetts General Hospital in Boston. Data indicate that obesity significantly increases the risk of endometrial and ovarian cancers and is associated with worse outcomes.

BOSTON—Recognizing steroid-induced hyperglycemia early and addressing it promptly can prevent significant ad - verse effects associated with this complication. Educating patients on the importance of and methods for maintaining good blood glucose control helps mitigate damage to the vascular system and kidneys from hyperglycemia. It also lessens susceptibility to infection, a complication of hyperglycemia that is of serious concern in immunocompromised patients.

Page 40 of 45
Results 391 - 400 of 442